CD28 and non-Hodgkin lymphoma: Both CD19-targeting CD28 G2 CAR-T cells and G3 CAR-T cells with both CD28 and 4-1BB co-stimulatory domains were tested in patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) in a dual G2/G3 CAR-T cell product injection study (NCT01853631), with a ~55% ORR reported in the targeted population [51].